 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...7891011121314151617...99100» |
- Piqray (alpelisib) / Novartis
Impact of time to progression (TTP) on CDK4/6 inhibitor (CDK4/6i) therapy on progression-free survival (PFS) in HR+/HER2-/PIK3CA-mutated advanced breast cancer (ABC) patients (pts) treated with alpelisib plus endocrine therapy (ALP+ET): An exploratory analysis of the METALLICA trial (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_469;
P2
These data suggest that duration of prior CDK4/6i exposure may be associated with PFS in HR+/HER2-/PIK3CA-mutated ABC pts treated with ALP+ET. Progression within the 1st year of prior CDK4/6i-based regimen seems to be prognostic of less favorable outcomes.
- Kisqali (ribociclib) / Novartis
Drug-drug interactions and their impact on clinical outcomes and adverse events in hormone receptor (HR)+/HER2- advanced breast cancer patients treated with ribociclib + letrozole: Insights from the BioltaLEE Trial (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_460;
P3
No difference in AEs was detected among the groups, except for AST elevation. Our study highlights the importance of evaluating DDI and of therapeutic reconciliation to maximize oncological treatment efficacy in this setting and lays the foundations for further research.
- letrozole / Generic mfg., exemestane / Generic mfg.
Letrozole and exemestane as serum estrogen suppressors during neoadjuvant therapy in breast cancer patients: a head-to-head comparison (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_285;
The findings indicate that the well-documented lack of cross-resistance between these drugs in clinical settings, allowing sequential therapy in MBC, is likely due to mechanisms beyond estrogen suppression. Our research group is currently investigating several additional, hithero unknown anti-tumor effects during exemestane therapy.
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial completion, Metastases: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Mar 19, 2024
P2, N=30, Completed, Sponsor: City of Hope Medical Center
Our research group is currently investigating several additional, hithero unknown anti-tumor effects during exemestane therapy. Active, not recruiting --> Completed
- | Verzenio (abemaciclib) / Eli Lilly
Trial completion date: Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov) - Mar 18, 2024
P2, N=60, Not yet recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Trial completion date: Mar 2025 --> Jun 2026
- | letrozole / Generic mfg.
Enrollment change: Assessment of the Efficacy of Letrozole in the Treatment of Ectopic Pregnancy (clinicaltrials.gov) - Mar 18, 2024
P1/2, N=150, Active, not recruiting, Sponsor: Tehran University of Medical Sciences
Trial completion date: Mar 2025 --> Jun 2026 N=75 --> 150
- | Ibrance (palbociclib) / Pfizer
Journal, Metastases: Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. (Pubmed Central) - Mar 18, 2024
With recovered survival data, the median OS was 53.8 (95% CI, 49.8 to 59.2) versus 49.8 months (95% CI, 42.3 to 56.4), respectively (HR, 0.92 [95% CI, 0.76 to 1.12]; one-sided P = .21). OS was not significantly improved with palbociclib plus letrozole compared with placebo plus letrozole.
- ||| letrozole / Generic mfg.
New P1 trial: LEILA-1: Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women (clinicaltrials.gov) - Mar 17, 2024
P1, N=90, Recruiting, Sponsor: Rovi Pharmaceuticals Laboratories
- | metformin / Generic mfg., letrozole / Generic mfg.
Journal: Bushen Huoxue Recipe inhibits endometrial epithelial-mesenchymal transition through the transforming growth factor-?/nuclear factor kappa-B pathway to improve polycystic ovary syndrome-mediated infertility. (Pubmed Central) - Mar 17, 2024
are important targets of BSHX for treating infertility in PCOS. BSHX improves the inflammatory state of PCOS, intervenes in the endometrial EMT process through the TGF-?/NF-?B pathway, and restores endometrial pathological changes, further improving the pregnancy outcome in PCOS.
- | letrozole / Generic mfg., thyroxine / Generic mfg.
Trial completion date, Trial primary completion date: Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism (clinicaltrials.gov) - Mar 15, 2024
P=N/A, N=200, Recruiting, Sponsor: Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy
BSHX improves the inflammatory state of PCOS, intervenes in the endometrial EMT process through the TGF-?/NF-?B pathway, and restores endometrial pathological changes, further improving the pregnancy outcome in PCOS. Trial completion date: Feb 2024 --> May 2024 | Trial primary completion date: Jan 2024 --> Apr 2024
- Kisqali (ribociclib) / Novartis
NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2_ early breast cancer (EBC) (Hamburg Hall) - Mar 14, 2024 - Abstract #ESMOBC2024ESMO_BC_247;
With the majority of pts completing RIB tx, these data confirm that RIB-related AEs and dose-related adjustments occurred early, highlighting the importance of timely management of AEs. RIB was well-tolerated in NATALEE with current dose adjustment guidelines.
- atirmociclib (PF-07220060) / Pfizer
First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 in combination with endocrine therapy (ET) in patients (pts) with HR+/HER2_ metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors (CDK4/6i): safety and efficacy update (Hamburg Hall) - Mar 14, 2024 - Abstract #ESMOBC2024ESMO_BC_246;
P1/2
At data cutoff (Nov 1, 2023), 33 pts received PF-07220060 (300mg/400mg BID) in combination with letrozole or fulvestrant (Parts 1B + 1C). PF-07220060 + ET showed a favorable safety profile with few hematologic adverse events and infrequent dose modifications, and promising efficacy despite prior CDK4/6i treatment, irrespective of key mutations.
- Verzenio (abemaciclib) / Eli Lilly
Neoadjuvant study of 12 months of Abemaciclib plus Letrozole vs. Chemotherapy in HR+/HER2_ highly proliferative (Ki67_20%) breast cancer: CARABELA (GEICAM/2019-01) Trial (Hamburg Hall) - Mar 14, 2024 - Abstract #ESMOBC2024ESMO_BC_245;
P2
BC pts. However, ET/ABE showed similar RCB class distribution and CRR compared to CT.
- Ibrance (palbociclib) / Pfizer
Neoadjuvant letrozole and palbociclib versus chemotherapy in the NeoPAL study: a translational analysis (Munich Hall) - Mar 14, 2024 - Abstract #ESMOBC2024ESMO_BC_234;
P2
This comprehensive analysis strongly suggests that LP has as profound an effect on luminal tumours as chemotherapy, with regard to proliferation decrease, immune attraction and stromal changes associated with tumor response. These results provide rationale for future chemo-sparing studies in high-risk luminal breast cancer.
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
Journal: Observation on efficacy and underlying mechanism of cheek acupuncture on ovulation induction for infertile women with PCOS: Case series. (Pubmed Central) - Mar 12, 2024
This model provides an explanation for the regulatory effects of cheek acupuncture point stimulation on the Hypothalamic-Pituitary-Ovarian axis (HPO), which subsequently influences follicle development and ovulation in patients. Consequently, when cheek acupuncture therapy is applied alone or in combination with ovulation induction medication, patients have the ability to achieve successful pregnancy and experience a smooth delivery.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Verzenio (abemaciclib) / Eli Lilly
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer. (Pubmed Central) - Mar 12, 2024
At a willingness-to-pay threshold of 3 times gross domestic product per capita in China for 2023 ($37721.5/QALY), the cost-effectiveness probability of dalpiciclib plus NSAI was 77.42%. From the perspective of Chinese payers, dalpiciclib plus NSAI appears to be a cost-effective strategy compared with abemaciclib plus NSAI for the first-line treatment of patients with HR+/HER2- ABC in China.
- | Hiltonol (poly-ICLC) / Oncovir
Enrollment open, Trial completion date: Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ (clinicaltrials.gov) - Mar 12, 2024
P1, N=50, Recruiting, Sponsor: Finn, Olivera, PhD
From the perspective of Chinese payers, dalpiciclib plus NSAI appears to be a cost-effective strategy compared with abemaciclib plus NSAI for the first-line treatment of patients with HR+/HER2- ABC in China. Not yet recruiting --> Recruiting | Trial completion date: Jul 2027 --> Aug 2028
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal: A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer. (Pubmed Central) - Mar 12, 2024
P2
This four-drug neoadjuvant regimen shows promising pathological response with an acceptable safety profile in patients with TPBC. A randomized controlled trial (NCT05638594) of this regimen is being conducted.
- | Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date: ARIADNE: Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer (clinicaltrials.gov) - Mar 12, 2024
P2, N=370, Recruiting, Sponsor: Karolinska University Hospital
A randomized controlled trial (NCT05638594) of this regimen is being conducted. Trial completion date: Dec 2031 --> Apr 2032 | Trial primary completion date: Jun 2026 --> Apr 2027
- | Herceptin (trastuzumab) / Roche, Nerlynx (neratinib) / Puma
Trial completion date, Trial primary completion date: Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (clinicaltrials.gov) - Mar 12, 2024
P2, N=48, Recruiting, Sponsor: Ruth O'Regan
Trial completion date: Dec 2031 --> Apr 2032 | Trial primary completion date: Jun 2026 --> Apr 2027 Trial completion date: Feb 2024 --> May 2024 | Trial primary completion date: Jan 2024 --> May 2024
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Computational inhibition of aromatase: an enzyme associated with endometriosis | Poster Board #1715 (In-person; Poster Board #1715; Hall C (Ernest N. Morial Convention Center)) - Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_9873;
Our research was able to narrow down the pool of nearly 3000 isoflavanones to 5 molecules. These results reveal promising novel drug treatments for endometriosis through targeting aromatase.
- Cetrotide (cetrorelix) / EMD Serono
IN-VITRO FERTILIZATION INDUCED SEVERE ACUTE KIDNEY INJURY (SAT-213; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1481;
Early therapeutic interventions if not instituted properly could lead to mortality. The management of these patients entails hydration and albumin infusion.
- Data Visualization of Patterns of Adjuvant Endocrine Therapy Among Older Women With Hormone-Positive Early-Stage Breast Cancer () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_956;
In our study, data visualization methods were employed to simplify and clarify complex treatment patterns. We effectively showcased diverse AET drug usage trends and switching patterns, revealing differences by age, cancer stage, HER2 status, and index year.
- Kisqali (ribociclib) / Novartis
Understanding the Humanistic and Economic Burden Associated with Early-Stage HR+/HER2- Breast Cancer: A Systematic Literature Review () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_715;
EORTC-QLQ-C30 scores showed clinically meaningful deterioration from baseline among patients who received neoadjuvant ribociclib+letrozole (36% patients) or chemotherapy (68% patients). Existing treatment options in early-stage HR+/HER2- BC were associated with substantial healthcare resource use, economic burden and decrement in quality of life suggesting an unmet need for novel treatment approaches in this setting.
- Long-Term Survival Prediction in Early Breast Cancer: A Machine Learning Approach With Random Survival Forest () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_638;
The most impactful prognostic factors for mortality, irrespective of the cause, were similar between the two age groups. Cancer-related factors and cardiovascular comorbidities were key contributors to BC-caused and CVD-caused deaths respectively.
- Ibrance (palbociclib) / Pfizer
Real-World Evidence on Adherence to the First CDK 4/6 Inhibitor (Palbociclib) in Breast Cancer Patients From Romania () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_363;
Most patients received combination therapy with letrozole (46%) and exemestane (13%). While high adherence rates were observed among patients treated with palbociclib, it is important to note that the collected data FROM THE Romanian National Health Insurance House were limited, lacking information on potential adverse reactions that might lead to treatment discontinuation.
- ||| Bizengri (zenocutuzumab-zbco) / Merus, Partner Therap
Trial completion, Trial completion date: MCLA-128-CL02: MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. (clinicaltrials.gov) - Mar 6, 2024
P2, N=105, Completed, Sponsor: Merus N.V.
While high adherence rates were observed among patients treated with palbociclib, it is important to note that the collected data FROM THE Romanian National Health Insurance House were limited, lacking information on potential adverse reactions that might lead to treatment discontinuation. Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Jul 2023
- | letrozole / Generic mfg., aspirin / Generic mfg., dydrogesterone / Generic mfg.
Journal: Successful live birth of thin endometrium: A case report. (Pubmed Central) - Mar 6, 2024
It highlights that, with appropriate interventions, successful pregnancies remain attainable. For those with a thin endometrium, emphasis should extend beyond thickness, addressing ways to enhance both endometrial blood supply and morphology for improved pregnancy rates.
- ||| sacibertinib (Hemay022) / Tianjin Hemay Pharma
Trial completion, Combination therapy, Metastases: Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer (clinicaltrials.gov) - Mar 6, 2024
P1, N=55, Completed, Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd
For those with a thin endometrium, emphasis should extend beyond thickness, addressing ways to enhance both endometrial blood supply and morphology for improved pregnancy rates. Recruiting --> Completed
- Tumor evolution upon treatment pressure with aromatase inhibitors in locally advanced estrogen receptor positive breast cancer (Section 51) - Mar 5, 2024 - Abstract #AACR2024AACR_8913;
Recruiting --> Completed Abstract is embargoed at this time.
- Ibrance (palbociclib) / Pfizer
Mechanisms of endocrine resistance to letrozole, fulvestrant, and palbociclib are associated with increased sensitivity to hexyl-cuban-1-yl biguanide inhibitors of CYP3A4 mediated epoxyeicosatrienoic acid biosynthesis (Section 51) - Mar 5, 2024 - Abstract #AACR2024AACR_7469;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- sapanisertib (CB-228) / Calithera
Improving targeted therapy in female patients with lung squamous cell carcinoma (Section 26) - Mar 5, 2024 - Abstract #AACR2024AACR_5349;
P1, P2
These results suggest that the estrogen may play a key role in the observed pattern of female resistance to mTOR inhibition. As such, the goal of the current proposal is to evaluate the catalytic mTOR kinase inhibitor TAK228, in combination with anti-estrogen therapy as a therapeutic strategy to treat LUSC in females.
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Identifying the genetic basis for resistance to aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients (Section 46) - Mar 5, 2024 - Abstract #AACR2024AACR_5156;
Background: AIs, such as letrozole, anastrozole, and exemestane, are used to treat hormonal receptor positive (HR+) breast cancer (BC) patients. This study provides insights into the genetic basis of resistance to AIs in mBC patients, opening up possibilities for development of new treatments to overcome resistance.
- letrozole / Generic mfg.
Translational research to facilitate development of novel therapeutic combinations of letrozole for the treatment of glioblastoma (Section 30) - Mar 5, 2024 - Abstract #AACR2024AACR_4069;
It synergistically enhances the efficacy of the DNA alkylating agent temozolomide, one of the few approved chemotherapeutics for GBM, against patient-derived GBM cells...Employing patient-derived G43, G75 and JHH-136 GBM lines we assessed the influence of PARP inhibitors (olaparib, pamiparib, veliparib and niraparib) in combination with LTZ on cell viability and neurosphere growth...Overall, these results provide a strong foundation for pursuing further development of combination therapy of GBM with LTZ and PARP inhibitors. A careful assessment of the clinical efficacy and safety profile of these agents will further guide shortlisting combination of LTZ for pre-clinical and clinical development.
- Ablation of adenylosuccinate lyase retarded the cell proliferation and induces mitochondrial dysfunction in endocrine therapy resistant breast cancer cells (Section 26) - Mar 5, 2024 - Abstract #AACR2024AACR_3980;
In summary, our findings indicate that ADSL-mediated de novo purine synthesis is crucial for cell proliferation. Therefore, targeting ADSL may be a novel therapeutic approach for ER, ET-resistant breast cancer.
- Ibrance (palbociclib) / Pfizer
Prospective evaluation of predictive biomarkers for Palbociclib (P) and endocrine therapy (ET) benefit in hormone receptor (HR)-positive [+]/human epidermal growth factor receptor 2 (HER2)-negative [-] advanced breast cancer (ABC) patients (pts) from PARSIFAL clinical trial: The transFAL sub-study (Section 43) - Mar 5, 2024 - Abstract #AACR2024AACR_3643;
Proteomic and RNA analyses did not yield confirmable distinctive expression pattern between resistant/sensitive pts...CONCLUSIONS High Ki67 levels and CDK6 expression in the tumor and high ctDNA density, but not proteomic or RNA sequencing data, were associated to poor outcome in this analysis of pts treated with CDK4/6i and ET. This data adds to the growing evidence of poor prognosis biomarkers in this setting, highlighting the need of novel strategies for these pts.
- || letrozole / Generic mfg.
Clinical, Journal: Effect of endometrial injury on pregnancy outcomes in infertile women undergoing intrauterine insemination. (Pubmed Central) - Mar 5, 2024
They underwent ovulation induction using letrozole and gonadotropins...However, the spontaneous pregnancy rate after the II cycle was significantly higher in the endometrial injury group (p=0.02). Endometrial injury increases pregnancy rates in later cycles but not in the same II cycle.
- Ibrance (palbociclib) / Pfizer, Kadcyla (ado-trastuzumab emtansine) / Roche
Trial termination, Metastases: Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer (clinicaltrials.gov) - Mar 5, 2024
P1/2, N=3, Terminated, Sponsor: University of Kansas Medical Center
Endometrial injury increases pregnancy rates in later cycles but not in the same II cycle. Active, not recruiting --> Terminated; Low accrual
- || Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date, Metastases: ABIGAIL: ABemaciclib, ET (clinicaltrials.gov) - Mar 4, 2024
P2, N=162, Active, not recruiting, Sponsor: MedSIR
Active, not recruiting --> Terminated; Low accrual Trial completion date: May 2024 --> Jun 2025 | Trial primary completion date: Jan 2024 --> Jun 2024
- | letrozole / Generic mfg.
Trial primary completion date: Letrozole in Post-Menopausal Patients with Operable Hormone-Sensitive Breast Cancer (clinicaltrials.gov) - Mar 4, 2024
P2, N=61, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
Trial completion date: May 2024 --> Jun 2025 | Trial primary completion date: Jan 2024 --> Jun 2024 Trial primary completion date: Nov 2023 --> Nov 2024
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal: Dispersive liquid-liquid microextraction followed by sweeping micellar electrokinetic chromatography-tandem mass spectrometry for determination of six breast cancer drugs in human plasma. (Pubmed Central) - Feb 27, 2024
The method was applied to plasma samples from six women currently receiving breast cancer treatment. Determined concentrations of the drugs of interest agreed with concentrations found in clinical studies, thus proving the suitability of the developed method for therapeutic drug monitoring as a superior alternative to published LC-MS methods.
- | letrozole / Generic mfg.
Enrollment open: Endometrial Preparation in Frozen Embryo Transfer Cycles (clinicaltrials.gov) - Feb 25, 2024
P4, N=210, Recruiting, Sponsor: Rahem Fertility Center
Determined concentrations of the drugs of interest agreed with concentrations found in clinical studies, thus proving the suitability of the developed method for therapeutic drug monitoring as a superior alternative to published LC-MS methods. Not yet recruiting --> Recruiting
- | Herceptin (trastuzumab) / Roche
New P2 trial: Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer (clinicaltrials.gov) - Feb 25, 2024
P2, N=66, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | letrozole / Generic mfg., anastrozole / Generic mfg.
Preclinical, Journal: Exploring the Potential of Essential Oil from Plectranthus amboinicus Leaves against Breast Cancer: In vitro and In silico Analysis. (Pubmed Central) - Feb 24, 2024
Not yet recruiting --> Recruiting Among the EO constituents, 4-tert-butyl-2-(5-tert-butyl-2-hydroxyphenyl)phenol (4BHP) exhibited the highest dock score of -6.580
- |||||| Kisqali (ribociclib) / Novartis
Enrollment open: ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov) - Feb 22, 2024
P3, N=3100, Recruiting, Sponsor: Novartis Pharmaceuticals
Among the EO constituents, 4-tert-butyl-2-(5-tert-butyl-2-hydroxyphenyl)phenol (4BHP) exhibited the highest dock score of -6.580 Not yet recruiting --> Recruiting
- | letrozole / Generic mfg.
Enrollment change: GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients (clinicaltrials.gov) - Feb 22, 2024
P2/3, N=80, Recruiting, Sponsor: Xiaojun Chen
Not yet recruiting --> Recruiting N=118 --> 80
- | letrozole / Generic mfg.
Enrollment open: GOG-3088: Letrozole in Uterine Leiomyosarcoma (clinicaltrials.gov) - Feb 22, 2024
P2, N=40, Recruiting, Sponsor: GOG Foundation
N=118 --> 80 Not yet recruiting --> Recruiting
- | letrozole / Generic mfg.
Trial completion: LIBER: Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation (clinicaltrials.gov) - Feb 21, 2024
P3, N=170, Completed, Sponsor: UNICANCER
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | letrozole / Generic mfg.
Journal: Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial. (Pubmed Central) - Feb 20, 2024
However, in time-dependent DR analysis, BCI (H/I)-High patients experienced statistically significant benefit from ELT after 4y, whereas (H/I)-Low patients did not. Because BCI (H/I) has been validated as a predictive marker of EET benefit in other trials, additional follow-up may enable further characterization of BCI's predictive ability.
- || Ibrance (palbociclib) / Pfizer
Trial completion, Trial completion date: LACOG1018: Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer (clinicaltrials.gov) - Feb 20, 2024
P2, N=43, Completed, Sponsor: Latin American Cooperative Oncology Group
Because BCI (H/I) has been validated as a predictive marker of EET benefit in other trials, additional follow-up may enable further characterization of BCI's predictive ability. Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> May 2023